A ‘Leap’ Toward Humanity’s Destruction

Posted On Aug 18, 2021 By admin With Comments Off

Wellcome leap

This article originally appeared on Unlimited Hangout.

The world’s richest medical experiment footing, the Wellcome Trust, has teamed up with a pair of onetime DARPA leads who constructed Silicon Valley’s skunkworks to usher in an age of nightmarish surveillance, including children older and younger as 3 month old-fashioned. Their agenda can only advance if we allow it.

A UK nonprofit with ties to world immorality throughout the COVID-1 9 crisis as well as historical and current ties to the UK eugenics shift launched a world-wide health-focused DARPA equivalent last year. The move went predominantly unnoticed by both mainstream and independent media.

The Wellcome Trust, which has arguably been second only to Bill Gates in its ability to influence occurrences during the COVID-1 9 crisis and vaccination campaign, propelled its own world-wide equivalent of the Pentagon’s reticent experiment authority last year, officially to combat the “most pressing health challenges of our time.”

Though first thoughts of in 2018, this specific Wellcome Trust strategy was spun off from the Trust last-place May with $300 million in initial funding. It rapidly allured two onetime DARPA executives, who had previously served in the upper echelons of Silicon Valley, to manage and plan its portfolio of projects.

This world state DARPA, known as Wellcome Leap, seeks to achieve “breakthrough scientific and technological solutions” by or before 2030, with a focus on “complex world state challenges.” The Wellcome Trust is open about how Wellcome Leap will apply the approaches of Silicon Valley and venture capital firms to the health and life science sector.

Unsurprisingly, their three current programs are poised to develop incredibly invasive tech-focused, and in some cases overtly transhumanist, medical technologies, including a program exclusively focused on using neural networks( AI ), mobile sensors, and wearable brain-mapping tech “for childrens” 3 years old and younger.

This Unlimited Hangout investigation explores is not simply the four current programs of Wellcome Leap but also the person or persons behind it. The ensuing scene is of an fantastically malevolent projection that constitutes not only a great threat to current culture but to the future of humanity itself. An upcoming Unlimited Hangout investigation will examine the history of the Wellcome Trust along with its role in recent and current events.

Leap’s Leadership: Merging Man and Machine for the Military and Silicon Valley

The intentions of the Wellcome Leap are made clear by the woman chosen to lead it, former director of the Pentagon’s DARPA, Regina Dugan. Dugan began her career at DARPA in 1996; she preceded a counterterrorism task force in 1999 before leaving DARPA about a year later.

After departing DARPA, she cofounded her own venture capital firm, Dugan Ventures, and then became special adviser to the US Army’s vice chief of staff from 2001 to 2003, which coincides with the attacks of Afghanistan and Iraq. In 2005, she made a defense-focused tech conglomerate announced RedXDefense, which contracts with the military and specifically for DARPA.

In 2009, under the Obama administration, Dugan was appointed director of DARPA by Defense Secretary Robert Gates. Much was realise over her being the first female conductor of relevant agencies, but she is best retained at relevant agencies for her so-called “Special Forces” approach to innovation. During her term, she established DARPA’s now defunct Transformational Convergence Technology Office, which focused on social networks, synthetic biology, and machine intelligence.

Many of the themes previously to be organized by that position are now overseen by DARPA’s Biological Engineering Office, which was created in 2014 and focuses on everything “from programmable microbes to human-machine symbiosis.” The Biological Technologies Office, like Wellcome Leap, seeks a mix of “health-focused” biotechnology programs and transhumanist endeavors.

Right before leaving the top character at DARPA, Dugan greenlighted the agency’s initial investments in mRNA vaccine technology, which led to DARPA’s investments in Pfizer and Moderna shortly thereafter. The DARPA scientist who lobbied Dugan to back the program, Dan Wattendorf , now wreaks as the director of Innovative Technology Solutions at the Bill& Melinda Gates Foundation.

While Dugan’s efforts at DARPA are recollected lovingly by those in the national-security state, and likewise by those in Silicon Valley, Dugan was investigated for conflicts of interest during her occasion as DARPA’s director, as her conglomerate RedXDefense acquired millions in Department of Defense contracts during her tenure.

Though she had recused herself from any formal role at the company while conducting DARPA, she continued to hold a significant fiscal stake in the company, and a military investigation later concluded she had flouted moralities patterns to a significant degree.

Instead of being held accountable in any way, Dugan went on to become a top executive at Google, where she was brought on to manage Google’s Advanced Technology and Produce Group( ATAP ), which it had spun out of Motorola Mobility after Google’s acquisition of that companionship in 2012. Google’s ATAP was modeled after DARPA and filled other ex-DARPA officials besides Dugan.

At Google, Dugan oversaw various projections, including what is now the basis of Google’s “augmented reality” business, then known as Project Tango, as well as “smart” clothing in which multitouch sensors were woven into textiles. Another campaign that Dugan headed involved the use of a “digital tattoo” to unlock smartphones. Perhaps most controversially, Dugan was also behind the process of drafting a “digital authentication pill.”

According to Dugan, when the pill is swallowed, “your entire body becomes your authentication token.” Dugan enclose the pill and many of her other efforts at Google as working to fix “the mechanical inconsistency between humans and electronics” by producing technology that consolidates the human body with machines to going degrees.

While serving in this capacity at Google, Dugan chaired a committee at the 2013 Clinton Global Initiative announced “Game-Changers in Technology” and attended the 2015 Bilderberg meeting where AI was a primary topic of discussion.

In 2016, Dugan left Google for Facebook where she was chosen to be the first head of Facebook’s own DARP-Aequivalent research agency, then known as Building 8. DARPA’s ties to the origins of Facebook were discussed in a recent Unlimited Hangout report.

Under Dugan, Building 8 invested heavily in brain-machine interface technology, which has since raised the company’s “neural wearable” wristbands that claim to be able to anticipate movements of the pas and digits from ability signals alone. Facebook showcased prototypes of the project earlier this year.

Dugan left Facebook really eighteen months after joining Building 8, announcing her programmes “to focus on building and extending a new work, ” which was apparently a reference to Wellcome Leap. Dugan later said it was as if she had been training courses for her persona at Wellcome Leap ever since participate the labour force, making it as the spire of her career.

When asked in an interview earlier this year who the customer of Wellcome Leap are, Dugan dedicated a long-winded answer but basically responded that the project acts the biotech and pharmaceutical industries, international organisation such as the UN, and public-private partnerships.

In addition to her character at Wellcome, Dugan is also a member of the Council on Foreign Relations-sponsored taskforce on US Technology and Innovation policy, which was formed in 2019. Other members include LinkedIn’s Reid Hoffman, McKinsey Institute Global Chairman James Manyika, onetime head of Google Eric Schmidt and President Biden’s contentious top discipline adviser Eric Lander.

The other administration at Wellcome Leap, chief operating officer Ken Gabriel, has a background closely confined to Dugan’s. Gabriel, like Dugan, is a onetime program director at DARPA, where he produced the agency’s microelectromechanical arrangements( MEMS) research from 1992 to 1996.

He helped as deputy director of DARPA from 1995 to 1996 and became conductor of the Electronics Technology Office from 1996 to 1997, where he was reportedly responsible for about half of all federal electronics-technology investments. At DARPA, Gabriel worked closely with the FBI and the CIA.

Ken Gabriel- COO of Wellcome Leap. Source: Wellcome Leap

Gabriel left DARPA for Carnegie Mellon University, where he was in charge of the Office for Security Technologies in the aftermath of September 11, 2001. That bureau was created after 9/11 exclusively to help meet the national-security needs of the federal government, according to Carnegie Mellon’s announcement of the program.

Around that same time, Gabriel became regarded as “the architect of the MEMS industry” due to his past work at DARPA and his founding of the MEMS-focused semiconductor company Akustica in 2002. He helped as Akustica’s chairman and chief technology officer until 2009, at which epoch he returned to work at DARPA where he sufficed as the agency’s deputy director, succeeding instantly under Regina Dugan.

In 2012, Gabriel followed Dugan to Google’s Advanced Technology and Concoction Group, which he was actually responsible for creating. According to Gabriel, Google cofounders Larry Page and Sergey Brin duty Gabriel with creating “a private sector ground-up model of DARPA” out of Motorola Mobility. Regina Dugan was placed in charge, and Gabriel again provided as her deputy.

In 2013, Dugan and Gabriel co-wrote a piece for the Harvard Business Review about how DARPA’s “Special Forces” innovation approach could change both the public and private sectors if more widely applied.

Gabriel left Google in 2014, well before Dugan, to serve as the president and CEO of Charles Stark Draper Laboratories, better known as Draper Labs, which develops “innovative technology solutions” for the national-security community, with a focus on biomedical systems, vigor, and space technology. Gabriel held that position until he abruptly resigned in 2020 to co-lead Wellcome Leap with Dugan.

In addition to his capacity at Wellcome, Gabriel is also a World Economic Forum “technology pioneer” and on the board of directors of Galvani Bioelectronics, a seam venture of GlaxoSmithKline, which is intimately linked to the Wellcome Trust, and the Google subsidiary Verily.

Galvani focuses on the development of “bioelectronic medicines” that involve “implant-based modulation of neural signals” in an overt pushing by the pharmaceutical industry and Silicon Valley to normalize transhumanist “medicines.”

The longtime chairman of the board of Galvani, on which Gabriel serves, was Moncef Slaoui, who led the US COVID-1 9 inoculation development and dissemination platform Action Warp Speed. Slaoui was relieved of its own position at Galvani this past March over well-substantiated claims of sexual harassment.

Jeremy Farrar, Pandemic Narrative Manager

While Dugan and Gabriel ostensibly guide the clothe, Wellcome Leap is the brainchild of Jeremy Farrar and Mike Ferguson, who serve as its administrators. Farrar is the director of the Wellcome Trust itself, and Ferguson is deputy chair of the Trust’s board of governors.

Farrar has been administrator of the Wellcome Trust since 2013 and has been actively involved in critical decision making at the highest level globally since the opening up of the COVID crisis. He is also an agenda contributor to the World Economic Forum and cochaired the WEF’s Africa meeting in 2019.

Farrar’s Wellcome Trust is also a WEF strategic partner and cofounded the COVID Action Platform with the WEF. Farrar was more recently behind the creation of Wellcome’s COVID-Zero initiative, which is also held to the WEF.

Farrar has enclose that initiative as “an opportunity for companies to advance the science which will eventually reduce business disruption.” Thus far it has reassured titans of finance, including Mastercard and Citadel, to invest millions in research and development at societies favored by the Wellcome Trust.

Wellcome Trust Director Jeremy Farrar with NTI Co-Chairman Sam Nunn, who led the 2001 Dark Winter exercise.

Source: NTI.com

Some of Wellcome’s controversial medical-research projects in Africa, as well as its ties to the UK eugenics change, were investigated in a December article published at Unlimited Hangout.

That report too explores the intimate communications of Wellcome to the Oxford-AstraZeneca COVID-1 9 inoculation, the purpose of applying which has now been restricted or banned in several countries. As mentioned in the introduction, the Wellcome Trust itself is the subject of an upcoming Unlimited Hangout investigation( Area 2 ).

Jeremy Farrar, who was born in Singapore in 1961, had previously been lead of the Oxford University Clinical Research Unit in Ho Chi Minh City, starting in 1998. During that time, he authored innumerable epidemiological research papers. He claimed in a 2014 Financial Times article that his decision to move to Vietnam was due to his dislike for gathering residences full of grey men.

Southeast Asia was obviously a much less regulated environment for someone in the medical-research industry wishing to indulge in groundbreaking research. Although based in Vietnam, Farrar was sent by Oxford to numerous locatings around the globe to study plagues happening in real time.

In 2009, when swine influenza was unleashing chao in Mexico, Farrar jumped on a plane to dive right into the action, something he too did for subsequent global eruptions of Ebola, MERS, and avian flu.

Over the past year, many questions have arisen viewing exactly how much power Farrar holds over global public health policy. Recently, the US president’s chief medical consultant, Anthony Fauci, was forced to release his emails and correspondence from March and April 2020 at the request of the Washington Post.

The released emails divulge what appears to be a high-level conspiracy by some of the top medical experts in the US to falsely claim that COVID-1 9 could only have been of zoonotic lineage, despite indications to the contrary. The emails were heavily redacted as such emails usually are, supposedly to protect the information of the people involved, but the “( b )( 6) ” redactions also protect much of Jeremy Farrar’s input into these discussions.

Chris Martenson, fiscal investigate and post-doctorate student of neurotoxicology and founder of Peak Prosperity, has had some insightful observes on such matters, including asking why such protection has been offered to Farrar given that he is the director of a “charitable trust.” Martenson went on to question why the Wellcome Trust was involved at all in these high-level discussions.

One Fauci email, dated February 25, 2020, and sent by Amelie Rioux of the WHO, stated that Jeremy Farrar’s official character at that time was “to act as the board’s focal point on the COVID-1 9 outbreak, to represent and advise the board on the science of the outbreak and the financing of the response.”

Farrar had previously chaired the WHO’s Scientific Advisory Council. The emails likewise register the planning, within a ten-day period, of the SARS-CoV-2 “‘origins” paper, which was entitled “The Proximal Origin of SARS-CoV-2” and was accepted for book by Nature Medicine on March 17, 2020.

The paper claimed that the SARS-CoV-2 virus could only have come from natural causes as opposed to gain-of-function research, specific claims once contained as revelation in the mainstream but which has come under considerable inquiry in recent weeks.

Shaping the presentation of an beginning floor for a virus of world-wide relevance is something Farrar has been involved with before. In 2004-5, it was reported that Farrar and his Vietnamese colleague Tran Tinh Hien, the frailty director at the Hospital for Tropical Ailment, were the first to identify the re-emergence of the avian influenza( H5N1) in humans.

Farrar has narrated the root story on many occasions, territory: “It was a little girl. She caught it from a pet duck that had died and she’d dug up and reburied. She survived.” According to Farrar, its own experience motivated him to found a global network in conjunction with the World Health Organization to “improve regional responses to disease outbreaks.”

An article published by Rockefeller University Press’s Journal of Experimental Medicine in 2009 is dramatically entitled, “Jeremy Farrar: When Disaster Strikes.” Farrar, when referring to the H5N 1 lineage storey territory: “The WHO people–and this is not a criticism–decided it was unlikely that the child had SARS or avian influenza.

They left, but Professor Hien stayed behind to talk with the child and her mum. The girlfriend admitted that she had been quite sad in the previous days with the deaths among her domesticated duck. The girl and her friend had campaigned over burying the duck and, because of this argument, she had gone back, delve up the duck, and reburied it–probably so her friend wouldn’t know where it was buried.

With that autobiography, Professor Hien phoned me at home and said he was worried about the child. He took some swabs from the child’s nose and throat and bring them back to the hospital. That night the laboratory operated assessments on the samples, and they were positive for Influenza A.”

With Farrar now having been uncovered as an instrumental part of the team that crafted the official story regarding the lineages of SARS-CoV-2, his previous affirms about the beginning of past scourges should be scrutinized.

As the director of a “charitable trust, ” Jeremy Farrar is almost completely inscrutable for his involvement in crafting contentious narratives pertaining to the COVID crisis. He continues to be at the forefront of the world-wide response to COVID, in part by launching the Wellcome Leap Fund for “unconventional jobs, money at scale” as an overt attempt to create a world-wide and “charitable” version of DARPA.

Indeed, Farrar, in conceive Wellcome Leap, has slotted himself to be just as, if not more, instrumental in building the foundation for the post-COVID era as he was in building the foundation for the COVID crisis itself.

This is significant as Wellcome Leap CEO Regina Dugan has labeled COVID-1 9 this generation’s “Sputnik moment” that will launch a new age of “health innovation, ” much like the launching of Sputnik started a global technological “space age.” Wellcome Leap perfectly intends to lead the pack.

“Rulers” of the Gene-Sequencing Industry

In contrast to the overt DARPA, Silicon Valley, and Wellcome bonds of the others, the chairman of the board of directors of Wellcome Leap, Jay Flatley, has a different background. Flatley is the long-time head of Illumina, a California-based gene-sequencing hardware and software giant that is believed to currently dominate the field of genomics.

Though he stepped down from the board of Illumina in 2016, he has continued to serve as the executive chairman of its board of directors. Flatley was the first to be chosen for a lead point at Wellcome Leap, and he was responsible for suggesting Regina Dugan for the organization’s chief executive officer, according to a recent interrogation given by Dugan.

Illumina Campus. Source: Glassdoor

As a profile on Illumina in the business magazine Fast Company memoes, Illumina “operates behind the scenes, selling hardware and services to companies and research universities, ” among them 23 andMe. 23 andMe’s CEO, Anne Wojcicki, the sister of YouTube CEO Susan Wojcicki and the bride of Google cofounder Sergey Brin, told Fast Company, “It’s crazy. Illumina is like the ruler of this whole universe and no one knows that.”

The report aware of the fact that 23 andMe, like most firms that render DNA sequencing and analysis to shoppers, utilizes machines produced by Illumina.

In 2016, Illumina launched an “aggressive” five-year plan to “bring genomics out of research labs and into doctors’ offices.” Given the current state of things, peculiarly the world-wide approach toward gene-focused vaccines and therapies, that scheme, which concludes this year, could not have been any better timed.

Illumina’s current CEO, Francis DeSouza, previously held key uprights at Microsoft and Symantec. Also in 2016, Illumina’s executive units predict a future in which humen are gene measured from birth to grave for both health and commercial purposes.

Whereas most corporations have fought financially during the coronavirus pandemic, some have interpreted a big increase in profits. Illumina has watched its share price double since the beginning of the COVID crisis.

The company’s$ 1 billion plus in earnings during the last tax year was obviously helped by the quick approval of the NovaSEQ 6000 machines, which can test a large number of COVID samples more quickly than other designs. An type machine has a hefty price tag of nearly$ 1 million, and thus they are mostly found at elite facilities, private labs, and top-tier universities.

Jay Flatley, Executive Chairman, Illumina, speaking at World Economic Forum in Davos 2018. Source: WEF

In addition to his long-standing leadership character at Illumina, Jay Flatley is also a “digital member” of the World Economic Forum as well as the lead independent director of Zymergen, a WEF “tech pioneer” company that is “rethinking biology and reimagining the world.”

Flatley, who has also attended several Davos rallies, has addressed the WEF on the “promise of precision[ i.e ., gene-specific] medicine.”

At another WEF panel meeting, Flatley, alongside UK Health Secretary Matt Hancock, promoted the relevant recommendations of compiling genomic sequencing of children at birth the norm, claiming it had “the potential to change the healthcare system from reactive to preventative.”

Some at the panel called for the genomic sequencing of babies to eventually become mandatory.

Aside from Flatley as an individual, Illumina as a company is a WEF partner and plays a key role in its programme regarding the future of health care. A top Illumina executive also provides on the WEF’s Global Future Council on Biotechnology.

A New HOPE

Wellcome Leap currently has four planneds: Multi-Stage Psych, Delta Tissue, 1KD, and HOPE. HOPE was the first program to be announced by Wellcome Leap and stands for Human Organs, Physiology and Engineering. According to the full program description, HOPE aims “to leverage the strength of bioengineering to advance stem cells, organoids, and whole organ the mechanisms and linkages that recapitulate human physiology in vitro and rehabilitate vital affairs in vivo.”

human organs physiology and engineering Source: Wellcome Leap, https :// wellcomeleap.org/ hope /

HOPE consists of two main program aims. First, it seeks to “bioengineer a multiorgan pulpit that recreates human immunological responses with sufficient faithfulnes to double the predictive importance of a preclinical inquiry with respect to efficacy, toxicity and immunogenicity for therapeutic interventions.”

In other terms, this bioengineered stage mimicking human organs would be used to test the effects of pharmaceutical products, including inoculations, which could create a situation in which animal ordeals are replaced with inquiries on gene-edited and raised organs.

Though such an advance would certainly be helpful in the sense of reducing often unethical animal experimentation, trusting such a novel organization to allow medical treatments to go straight to the human-testing phase would also require trusting the institutions developing that organisation and its funders.

As it stands now, the Wellcome Trust has too many ties to pervert actors in the pharmaceutical industry, having initially begun as the “philanthropic” arm of UK drug giant GlaxoSmithKline, for anyone to trust what they are producing without actual independent confirmation, given the histories of some of their partners in fudging both animal and human clinical ordeal the necessary data for vaccines and other products.

The second goal of HOPE is to open up the use of machine-human hybrid parts for transplantation into human beings. That point focuses on restoring “organ purposes employing grown parts or biological/ synthetic composite systems” with the later goal of bioengineering a fully transplantable human part after several years.

Later on in the program description, however, the interest in merging the synthetic and biological becomes clearer when it positions: “The hour is right to foster synergies between organoids, bioengineering and immunoengineering technologies, and boost the state-of-the-art of in vitro human biology … by house controllable, accessible and scalable systems.”

The program description document also notes the interest of Wellcome in genetic-engineering approaches for the “enhancement of wanted assets and insertion of traceable markers” and Wellcome’s ambition to reproduce the building blocks of the human immune system and human organ plans through technological means.

Transhumanist Toddlers?

The second program to be pursued by Wellcome Leap is called “The First 1000 Days: Promoting Healthy Brain Networks, ” which is abbreviated as 1KD by the organization. It is arguably the most unsettling program because it seeks to use young children, specifically infants from three months to three-year-old toddlers, as its test subjects.

The program is being overseen by Holly Baines, who has ever served as strategy occurrence extend for the Wellcome Trust before assembling Wellcome Leap as the 1KD curriculum leader.

the first 1000 days Source: Wellcome Leap, https :// wellcomeleap.org/ 1kd /

1KD focuses primarily on developing “objective, scalable ways to assess a child’s cognitive health” by monitoring the brain development and purpose of newborns and toddlers, accepting practitioners to “risk-stratify children” and “predict responses to interventions” in developing brains.

The program description document notes that, up to this point in biography, “our primary space into the developing brain has been neuroimaging procedures and animal representations, which can help identify quantitative biomarkers of[ neural] system health and characterise system divergences underlying behaviours.” It then states that advances in technology “are opening added likelihoods in young infants.”

The program description goes on to say that artificial neural network, a sort of AI, “have demonstrated the viability of modelling network pruning process and the acquisition of complex actions in much the same way as a developing brain, ” while improvements in machine learning, another subset of AI, can now be used to extract “meaningful signals” from the mind of infants and young children.

These algorithms can then be used to develop “interventions” for young children regarded by other algorithms to be in danger of having underdeveloped brain function.

The document goes on to note the promise of “low-cost mobile sensors, wearables and home-based systems” in “providing a new opportunity to assess the influence and addiction of brain development on natural physical and social interactions.”

In other oaths, this program seeks to use “continuous visual and audio recordings in the home” as well as wearable designs on children to collect millions upon millions of data points. Wellcome Leap describes these wearables as “relatively unassuming, scalable electronic buttons that rally visual, auditory and flow data as well as interactive peculiarities( such as turn-taking, speeding and reaction times ). “

Elsewhere in the document there is a call to develop “wearable sensors that assess physiological quantifies predictive of brain health( e.g ., electrodermal task, rate of respiration, and heart rate) and wireless wearable EEG or eye-tracking technology” for use in babes and children three and under.

Like other Wellcome Leap programs, this technology is being developed with the intention of concluding it mainstream in medical science within the next five to ten years, meaning that this system–although made as a space to monitor children’s brain functioning to improve cognitive outcomes–is a recipe for total surveillance of babies and very young children as well as a means for altering their brain functioning as algorithms and Leap’s programmers see fit.

1DK has two main program purposes. The first is to “develop a fully integrated model and quantitive calculation an instrument of network developed as the first 1000 periods[ of life-time ], sufficient to predict EF[ director function] shaping before a child’s first birthday.”

Such a modeling, the specific characteristics reads, “should predict contributions of nutrition, the microbiome and the genome” on mentality shaping as well as the effects of “sensimotor and social interactions[ or shortcoming thereof] on system snipping processes” and EF outcomes. The second objective makes it clear that widespread adoption of such neurological-monitoring technologies in children and babes is the endgame for 1DK.

It states that the program plans to “create scalable methods for optimising promotion, avoidance, screening and therapeutic involvements to improve EF by at least 20% in 80% of children before senility 3. “

True to the eugenicist ties of the Wellcome Trust( to be explored more in-depth in Part 2 ), Wellcome Leap’s 1DK notes that “of interest are betters from underdeveloped EF to normative or from normative to well-developed EF across the population to deliver the broadest impact.”

One of the goals of 1DK is thus not considering sicknes or addressing a “global health populace challenge” but instead experimenting on the cognitive augmentation of children abusing intends developed by AI algorithms and invasive surveillance-based technology.

Another unsettling aspect of the program is its plan to “develop an in vitro 3D ability assembloid that replicates the time formation” of a developing brain that is akin to the prototypes put forward by monitoring the brain development of babies and children.

Later on, the program description calls this an “in-silico” prototype of a child’s brain, something of obvious interest to transhumanists who find such a development as a harbinger of the so-called singularity.

Beyond that, it appears that this in-silico and thus synthetic modeling of the mentality is planned to be used as the “model” to which infant and children brains are mold by the “therapeutic interventions” mentioned elsewhere in the program description.

It should be clear how ominous it is that an organization that brings together the worst “mad scientist” compulsions of both the NGO and military-research macrocosms is openly planning to conduct such experiments on the brains of newborns and toddlers, considering them as datasets and their intelligences as something to be “pruned” by machine “intelligence.”

Allowing such a program to advance unimpeded without pushback from the public would necessitate countenancing a perilous agenda targeting society’s youngest and most vulnerable members to potentially boost to a part where it is difficult to stop.

A “Tissue Time Machine”

The third and second-most recent program to join the Wellcome Leap lineup is called Delta Tissue, abridged by the organization as DT. Delta Tissue aims to create a scaffold that checks changes in human-tissue function and interactions in real meter, ostensibly to “explain the status of a disease in each person and better predict how that sicknes would progress.”

Referring to this platform as a “tissue time machine, ” Wellcome Leap considers Delta Tissue as being able to predict the onslaught of illnes before it comes while also allowing for medical interventions that “are targeted to the individual.”

delta tissue Source: Wellcome Leap, https :// wellcomeleap.org/ delta-tissue /

Well before the COVID era, accuracy medication or medication “targeted or tailor-make to the individual” has been a code phrase for treatments based on patients’ genetic data and/ or for managements that adjust nucleic acid( e.g ., DNA and RNA) function itself. For example, the US government defines “precision medicine” as “an surfacing approaching for disease medicine and prevention that takes into account individual variability in genes, environment, and life-style for each person.”

Similarly, a 2018 article published in Technology notes that, in oncology, “precision and personalized medicine … promotes the developed at specialized medications for each specific subtype of cancer, based on the measurement and manipulation of key patient genetic and omic data( transcriptomics, metabolomics, proteomics, etc .). “

Prior to COVID-1 9 and the inoculation roll out, the mRNA vaccine technology used by the DARP-Afunded firms Moderna and Pfizer were sold as being precision medicine treatments and were largely referred to as “gene rehabilitations” in media reports.

They were also promoted heavily as a revolutionary procedure of treating cancer, constituting it unsurprising that the Delta Tissue curriculum at Wellcome Leap would use a same justification to develop a program that aims to offer accommodated gene therapies to parties before the onslaught of a disease.

This Delta Tissue platform works to combine “the latest cell and material profiling technologies with recent advances in machine learning, ” that is, AI.

Given Wellcome Leap’s connections to the US armed, it is worth noting that the Pentagon and Google, both onetime employers of Wellcome Leap CEO Regina Dugan and COO Ken Gabriel, have been working together since last September on using AI to predict disease in humans, first focusing on cancer before expanding to COVID-1 9 and every sicknes in between.

The Delta Tissue platform appears to have associated passions, as its program description makes clear that the program ultimately aims to use its stage for a multitude of cancers and infectious diseases.

The ultimate goal of this Wellcome Leap program is “to eradicate the stubbornly challenging cankers that cause so much suffering around the world.” It plans to do this through AI algorithms, however, which are never 100 percentage accurate in their predictive clevernes, and with gene-editing treatments, nearly all of which are novel and have not been well tested.

That latter point is important given that one of the main methods for gene-editing in humans, CRISPR, has been found in countless studies to cause great damage to the DNA, impairment that is largely irreparable( watch here, here and here ).

It seems plausible that a person placed on such a hi-tech medical treatment path will continue to need a never-ending series of gene-editing medicines and perhaps other invasive hi-tech therapies to mitigate and control the effects of cumbersome gene splicing.

Total Surveillance to Treat “Depression”

Wellcome Leap’s most recent program, propelled this very week, is called “Multi-Channel Psych: Revealing Mechanisms of Anhedonia” and is officially focused on creating “complex, biological” medications for depression.

multi channel psych Source: Wellcome Leap, https :// wellcomeleap.org/ mcpsych /

Those behind Wellcome Leap frame the problem they aim to tackle with this program as follows 😛 TAGEND

“We understand that synaptic attachments serve as the currency of neural communication, and that strengthening or undermining these acquaintances can facilitate learning brand-new behavioral approaches and ways of looking at the world.

Through studies in both animal patterns and humans, we have discovered that emotional states are encoded in complex neural net undertaking blueprints, and that instantly changing these structures via brain stimulant can change feeling. We also know that disruption of these delicately poised structures can be achieved through neuropsychiatric illness.”( emphasis added)

They add that “biologically based treatments” for recession “are not being joined to the biology of the human beings they’re being used in, ” and, thus, medications for feeling need to be tailored “to the specific biology” of individual patients. They be made clear that what needs to be addressed in order to making this personal modifications to treatment is to gain “easy access to the biological substrate of depression–i.e. the brain.”

Wellcome Leap’s program description notes that this effort will focus specifically on anhedonia, which it defines as “an impairment in the effort-based reward system” and as a “key symptom of recession and other neuropsychiatric illnesses.” Notably, in the fine print of the document, Wellcome Leap governments 😛 TAGEND

“While there are many definitions of anhedonia, we are less interested in the investigation of increased consummatory please, the general experience of desire, or the inability to experience pleasure. Rather, as per the specific characteristics above, we will prioritize investigations of anhedonia as it relates to ailments in the effort-based reward system–e.g. abbreviated motivation to complete exercises and lessened ability to apply effort to achieve a goal.”

In other paroles, Wellcome Leap is only interesting to treating aspects of depression that is in conflict with an individual’s work abilities , not in improving an individual’s quality or enjoyment of life.

Leap documents, in discussing its goals, that it seeks to develop examples for how patients respond to treatments that include “novel or existing behavior modification, psychotherapy, remedy, and neurostimulation options” while also capturing an individual’s “genome, phenome[ the sum of an individual’s phenotypic characteristics ],[ neural] structure connectivity, metabolome[ the sum of an individual’s metabolic traits ], microbiome, remuneration processing plasticity status, ” among others.

It ultimately aims to predict the relationship between an individual’s genome to how “reward processing” parts in the intelligence. It implies that the data used to create this simulation should involve the use of wearables, stating that researchers “should seek to leverage high frequency patient-worn or in-home assessments in addition to those obtained in the clinic, hospital or laboratory.”

One of the primary research areas included in the program gazes to “develop new scalable estimation tools for reliable and high-density quantification of climate( both subjectively reported and objectively quantified via biometrics such as voice, facial expression, etc .), sleep, shift, reward system functioning, act/ incitement/ force ranks, social interaction, caloric uptake, and HPA axis output in real-world situations.”

The HPA( hypothalamic-pituitary-adrenal) axis is mentioned throughout the document, and this is significant as it is both a negative and positive feedback system regulating the mechanisms of stress actions, immunity, and too birthrate in the human body.

The latter is of particular importance having regard to the Wellcome Trust’s ties to the UK eugenics gesture. It is likewise worth mentioning that some commercially available wearables, such as Amazon’s Halo, already quantify feeling, sleep, and movement.

The program’s writers go even further than the above in terms of what they wish to monitor in real time, stating, “We specifically encourage the development of non-invasive technology to instantly interrogate human psyche state.” Samples include “a non-invasive spinal sound equivalent, ” “behavioral or biomarker examinations of neural plasticity, ” and “single-session neural monitoring abilities that define a treatment-predictive mentality state.”

In other utterances, this Wellcome Leap planned and its scribes seek to develop “non-invasive” and, likely, wearable engineering capable of monitoring an individual’s mood, facial expressions, social interactions, struggle and incitement, and potentially even thoughts in order to better “directly interrogate human mentality state.”

To think that such a invention would stay only in the realm of research is naive, especially given that WEF dignitaries have honestly spoken at Davos confronts about how authorities plan to use such technology widely on its own population as a means of pre-emptively targeting would-be difference and ushering in an era of “digital dictatorships.”

The focus on treating simply the aspects of depression that interfere with a person’s work further suggests that such technology, formerly developed, would be used to ensure “perfect worker” behavior in industries where human workers are rapidly being replaced with AI and machines, necessitating the rulers can be more selective about which people continue to be employed and which do not.

Like other Wellcome Leap planneds, if ended, the outcome of the the Multi-Channel Psych program will likely be used to ensure a population of obedient automatons whose advances and thinkings are heavily surveilled and monitored.

The Last-place Leap for the purposes of an Old Agenda

Wellcome Leap is no small endeavor, and its leads have the funding, affect, and connections to make their dreams reality. The organization’s leadership includes the key action behind Silicon Valley’s pushing to commercialize transhumanist tech( Regina Dugan ), the “architect” of the MEMS industry( Ken Gabriel ), and the “ruler” of the burgeoning genetic-sequencing industry( Jay Flatley ).

It also benefits from the funding of the world’s largest medical-research foundation, the Wellcome Trust, which is also one of the leading forces in mold genetics and biotechnology research as well as state program globally.

A 1994 Sunday Times investigation into the Trust noticed … … that “through[ Wellcome Trust] awards and sponsorships, government agencies, universities, hospitals and scientists are forced all over the world. The trust dispenses more fund to prisons than even the British government’s Medical Research Council.” It then memorandum 😛 TAGEND

“In powers on the building’s first floor, decisions are reached that affect lives and health on scales equivalent with minor fights. In the conference room, high-pitched above wall street, and in the session dormitory, in the basement, decrees in biotechnology and genetics are handed down that will help shape the human race.”

Little has changed regarding the Trust’s influence since that commodity was published. If anything, its affect on experiment routes and decisions that will “shape the human race” has only grown. Its ex-DARPA officials, who have invested their vocations boosting transhumanist engineering in both the public and private sectors, have overlapping purposes with those off Wellcome Leap.

Dugan’s and Gabriel’s commercial jobs in Silicon Valley reveal that Leap presided over by those who have long sought to advance the same engineering for profit and for surveillance. This drastically deteriorates Wellcome Leap’s claim to now be prosecuting new information and communication technologies to only improve “global health.”

type from your brain Regina Dugan’s Keynote at Facebook F8 2017. Source: YouTube

Indeed, as this report has shown, most of these technologies would be used in a deeply disturbing era of mass surveillance over both the external and internal activities of human beings, including young children and babes, while also creating a brand-new era of prescription located mainly on gene-editing rehabilitations, the risks of which are considerable and too routinely downplayed by its promoters.

When one understands the insinuate ligament that has long existed between eugenics and transhumanism, Wellcome Leap and its goals constitute excellent feel. In a recent commodity written by John Klyczek for Unlimited Hangout, it was noted that the first director general of UNESCO and former president of the UK Eugenics Society was Julian Huxley, who coined the period “transhumanism” in his 1957 diary New Bottles for New Wine.

As Klyczek wrote, Huxley argued that “the eugenic goals of biologically engineering human progression is advisable to refined through transhumanist technologies, which combine the eugenic methods of genetic engineering with neurotech that consolidates human beings and machines into a new organism.”

Earlier, in 1946, Huxley noted in his image for UNESCO that it was essential that “the eugenic problem is examined with the greatest care and that the public mind is informed of the issues at post so that much that is now unbelievable may at least become thinkable, ” an stunning affirmation to construct so soon after the end of World War II.

Thanks in big responsibility to the Wellcome Trust and its affect on both plan and medical research over the course of several decades, Huxley’s dream of rehabilitating eugenics-infused science in the post-World War II era could soon becomes a reality. Unsurprisingly, the Wellcome Trust hosts the archive of the formerly Huxley-led Eugenics Society and still boasts close ties to its successor organization, the Galton Institute.

The over-riding question is: Will we allow ourselves continued to provide influenced into allowing transhumanism and eugenics to be openly sought and normalized, including through initiatives like those of Wellcome Leap that seek to use newborn and toddlers as test subjects to advance their frightening see for humanity?

If well-crafted advertising slogans and media campaigns painting seeings of utopia such as “a world without disease” are all that is needed to convince us to give up our future and our children’s future to military operatives, corporate managers, and eugenicists, then there is little left of our humanity to surrender.